Bylvay, Kayfanda in EU, safely treats PFIC: Real-world study
In real-world use, Kayfanda (odevixibat) — available under the brand name Bylvay in the U.S. — lowered blood bile acid levels and eased…
News
IBAT inhibitors have potential to boost life quality for patients
Alagille syndrome comes with a high clinical, economic, and quality-of-life burden for patients and their families, but new treatments such as Livmarli (maralixibat)…
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
Cour’s CNP-104 granted FDA orphan drug status for treating PBC
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).
Maralixibat Phase 3 trial for cholestasis-related itch is enrolling
Enrollment is ongoing in a Phase 3 clinical trial that’s designed to evaluate Mirum Pharmaceuticals’ maralixibat for treatment-resistant itching, or pruritus, associated with rare…
Gut bacteria is involved in systems that help regulate fat in liver: Study
Biochemical crosstalk between the body’s own cells and microbes living in the intestines helps regulate the accumulation of fat in the liver, a new study…
Robotic-assisted Kasai liver surgery may help biliary atresia outcomes
A robotic-assisted Kasai surgical procedure results in less blood loss, faster bowel function recovery, and greater rates of clearing jaundice at three and six…
ABI-4334 shows promise in hepatitis B Phase 1b trial: Data
Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…
Liver donor type may sway primary sclerosing cholangitis outcomes
Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative to those from a deceased…
New TJP2 mutations detected in girl with mild PFIC4
A combination of two new mutations in the TJP2 gene was identified as the cause of a mild form of progressive familial intrahepatic cholestasis type 4 (PFIC4) in…
Recent Posts
- Bylvay, Kayfanda in EU, safely treats PFIC: Real-world study
- How I’m learning to cope with challenges as a rare disease parent
- IBAT inhibitors have potential to boost life quality for patients
- Trial of HBV treatment candidate now enrolling final patient group
- Cour’s CNP-104 granted FDA orphan drug status for treating PBC